Crescent Biopharma, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-153.9M | $-37.9M | $-36.9M | $-46.7M | $-63.4M | $-51.0M | $-57.9M | $-48.3M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $84.0K | $35.2K | $153.3K | $207.1K | $264.6K | $270.8K | $279.2K | $275.1K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $13.3M | $4.7M | $3.5M | $3.9M | $6.1M | $6.9M | $6.2M | $4.6M |
| Net Cash from Operating Activities | $-71.5M | $-31.1M | $-34.9M | $-46.5M | $-57.5M | $-39.2M | $-52.0M | $-43.3M |
| Investing Activities | ||||||||
| Capital Expenditures | $919.0K | $10.0K | $21.4K | $84.2K | $14.9K | $68.5K | $144.9K | $125.6K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-72.9M | $20.0K | $-21.4K | $-84.2K | $-14.9K | $-68.5K | $-144.9K | $-125.6K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $323.0M | $5.4K | $28.8M | $4.2M | $10.7M | $18.1M | $412.9K | $129.4M |
| Net Change in Cash | $178.5M | $-31.1M | $-6.1M | $-42.4M | $-46.8M | $-21.2M | $-51.7M | $86.0M |
| Free Cash Flow | $-72.5M | $-31.1M | $-34.9M | $-46.5M | $-57.5M | $-39.3M | $-52.1M | $-43.5M |